PL358230A1 - Genetic silencing - Google Patents

Genetic silencing

Info

Publication number
PL358230A1
PL358230A1 PL01358230A PL35823001A PL358230A1 PL 358230 A1 PL358230 A1 PL 358230A1 PL 01358230 A PL01358230 A PL 01358230A PL 35823001 A PL35823001 A PL 35823001A PL 358230 A1 PL358230 A1 PL 358230A1
Authority
PL
Poland
Prior art keywords
genetic silencing
silencing
genetic
Prior art date
Application number
PL01358230A
Other languages
English (en)
Polish (pl)
Inventor
Michael Wayne Graham
Robert Norman Rice
Kathleen Margaret Murphy
Kenneth Clifford Reed
Original Assignee
Benitec Australia Ltd
The State Of Queensland Through Its Department Ofprimary Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ6363A external-priority patent/AUPQ636300A0/en
Priority claimed from AUPR2700A external-priority patent/AUPR270001A0/en
Application filed by Benitec Australia Ltd, The State Of Queensland Through Its Department Ofprimary Industries filed Critical Benitec Australia Ltd
Publication of PL358230A1 publication Critical patent/PL358230A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL01358230A 2000-03-17 2001-03-16 Genetic silencing PL358230A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ6363A AUPQ636300A0 (en) 2000-03-17 2000-03-17 Genetic silencing
AUPR2700A AUPR270001A0 (en) 2001-01-24 2001-01-24 Genetic silencing

Publications (1)

Publication Number Publication Date
PL358230A1 true PL358230A1 (en) 2004-08-09

Family

ID=25646282

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01358230A PL358230A1 (en) 2000-03-17 2001-03-16 Genetic silencing

Country Status (12)

Country Link
US (1) US20030182672A1 (https=)
EP (1) EP1272629A4 (https=)
JP (2) JP2003527856A (https=)
KR (1) KR20020097198A (https=)
CN (1) CN1426466A (https=)
AU (1) AU2001240375A1 (https=)
BR (1) BR0109269A (https=)
CA (1) CA2403162A1 (https=)
GB (1) GB2377221B (https=)
MX (1) MXPA02009069A (https=)
PL (1) PL358230A1 (https=)
WO (1) WO2001070949A1 (https=)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CN1378602A (zh) 1999-08-26 2002-11-06 卡尔根尼有限公司 含修饰的多不饱和脂肪酸的植物
US7067722B2 (en) 1999-08-26 2006-06-27 Monsanto Technology Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7531718B2 (en) 1999-08-26 2009-05-12 Monsanto Technology, L.L.C. Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1229134A3 (en) 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2005078097A2 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP2345720A3 (en) 2001-07-12 2012-01-25 University of Massachusetts In vivo production of small interfering RNAs that mediate gene silencing
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
ES2386775T3 (es) 2001-07-23 2012-08-30 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos
US20050037989A1 (en) * 2001-08-27 2005-02-17 Lewis David L. Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AR039113A1 (es) 2002-03-21 2005-02-09 Monsanto Technology Llc Construcciones de acidos nucleicos y metodos para producir composiciones de aceites de semillas alteradas
US7566813B2 (en) 2002-03-21 2009-07-28 Monsanto Technology, L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
US7166771B2 (en) 2002-06-21 2007-01-23 Monsanto Technology Llc Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
US20040172667A1 (en) 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
AU2003256615A1 (en) 2002-08-12 2004-02-25 New England Biolabs, Inc. Methods and compositions relating to gene silencing
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7122361B2 (en) 2002-10-10 2006-10-17 Wyeth Compositions employing a novel human kinase
CA2503491A1 (en) 2002-10-24 2004-05-06 Wyeth Calcineurin-like human phosphoesterase
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
US7297525B2 (en) 2002-11-27 2007-11-20 Wyeth Composition employing a novel human kinase
WO2005009346A2 (en) * 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
WO2005019440A1 (en) 2003-08-20 2005-03-03 Northern Sydney And Central Coast Area Health Service Methods for enhancing embryo viability
EP1672064A4 (en) * 2003-09-22 2006-12-20 Riken EFFICIENT METHOD FOR GENERATING AN INVERTED REPEAT DNA STRUCTURE
DE10351149A1 (de) * 2003-11-03 2005-06-30 Beiersdorf Ag Oligoribonukleotide zur Behandlung von unerwünschter Pigmentierung der Haut und der Haare durch RNA-Interferenz
WO2005062881A2 (en) 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
AU2005238034A1 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Of New York Inhibition of hairless protein mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
JP2008515458A (ja) 2004-10-13 2008-05-15 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド 線虫抵抗性の遺伝子組換え植物
CN101213301B (zh) 2005-05-31 2013-02-27 德福根有限公司 用于防治昆虫和蜘蛛类动物的RNAi
EP2980220A1 (en) 2005-09-20 2016-02-03 BASF Plant Science GmbH Improved methods controlling gene expression
US8093369B2 (en) 2005-10-11 2012-01-10 Ben Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of VDAC1 and uses thereof
CA2631621C (en) 2005-11-29 2019-08-06 Cambridge Enterprise Limited Markers for breast cancer including rs2981582
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
CN101421406B (zh) 2006-02-13 2016-08-31 孟山都技术有限公司 用于产生改变的种子油组成的核酸构建体和方法
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
AU2007276388A1 (en) 2006-07-21 2008-01-24 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
EP2124522B1 (en) 2007-02-05 2011-11-16 National University of Singapore Putative cytokinin receptor and methods for use thereof
PL2129680T3 (pl) 2007-03-21 2015-10-30 Brookhaven Science Ass Llc Łączone kompozycje cząsteczek antysensownych o strukturze spinki do włosów oraz sposoby modulacji ekspresji
WO2009129558A1 (en) 2008-04-24 2009-10-29 Newsouth Innovations Pty Limited Cyanobacteria saxitoxin gene cluster and detection of cyanotoxic organisms
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
US9157097B2 (en) 2008-09-25 2015-10-13 Proteovec Holding, L.L.C. Vectors for production of growth hormone
WO2010036976A2 (en) 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
AR075549A1 (es) 2008-09-29 2011-04-20 Monsanto Technology Llc Evento transgenico de soja mon87705 y metodos para detectar el mismo
MY159849A (en) 2008-12-22 2017-02-15 Lek Pharmaceuticals Mammalian expression vector
EP2241627A1 (en) * 2009-04-17 2010-10-20 LEK Pharmaceuticals d.d. Mammalian expression vector
EP2417263B1 (en) 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors
WO2010139026A1 (en) 2009-06-05 2010-12-09 Centenary Institute Of Cancer Medicine And Cell Biology Therapeutic and diagnostic molecules
EP3000885B1 (en) 2009-12-18 2018-07-25 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
PL3265563T3 (pl) 2015-02-02 2021-09-13 Meiragtx Uk Ii Limited Regulacja ekspresji genów poprzez modulację alternatywnego splicingu za pośrednictwem aptamerów

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4766072A (en) * 1985-07-17 1988-08-23 Promega Corporation Vectors for in vitro production of RNA copies of either strand of a cloned DNA sequence
US5231020A (en) * 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5034323A (en) * 1989-03-30 1991-07-23 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5714323A (en) * 1991-08-30 1998-02-03 The University Of Medecine And Dentistry Of New Jersey Over expression of single-stranded molecules
CA2130454C (en) * 1992-02-19 2008-04-08 William G. Dougherty Production of viral resistant plants via introduction of untranslatable plus sense viral rna
DE4208107A1 (de) * 1992-03-13 1993-09-16 Bayer Ag Pseudorabies-virus (prv)-polynukleotide und ihre verwendung zur herstellung von virusresistenten eukaryotischen zellen
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5686649A (en) * 1994-03-22 1997-11-11 The Rockefeller University Suppression of plant gene expression using processing-defective RNA constructs
US6054299A (en) * 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
CA2262776C (en) * 1996-08-02 2005-03-08 Genesense Technologies, Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
US5814500A (en) * 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
AU2005299A (en) * 1997-12-20 1999-07-12 Genencor International, Inc. Fluidized bed matrix granule
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO1999049029A1 (en) * 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
NZ507093A (en) * 1998-04-08 2003-08-29 Commw Scient Ind Res Org Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6423885B1 (en) * 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
ATE507300T1 (de) * 2000-06-23 2011-05-15 Du Pont Rekombinante konstrukte und ihre verwendung bei der reduzierung der genexpression
US7109393B2 (en) * 2000-08-15 2006-09-19 Mendel Biotechnology, Inc. Methods of gene silencing using inverted repeat sequences

Also Published As

Publication number Publication date
JP2003527856A (ja) 2003-09-24
AU2001240375A1 (en) 2001-10-03
US20030182672A1 (en) 2003-09-25
JP2011229542A (ja) 2011-11-17
CN1426466A (zh) 2003-06-25
EP1272629A4 (en) 2004-12-22
GB2377221B (en) 2004-08-18
WO2001070949A1 (en) 2001-09-27
GB0224195D0 (en) 2002-11-27
CA2403162A1 (en) 2001-09-27
KR20020097198A (ko) 2002-12-31
GB2377221A (en) 2003-01-08
BR0109269A (pt) 2002-12-17
MXPA02009069A (es) 2004-04-05
EP1272629A1 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
GB2377221B (en) Genetic silencing
GB9925459D0 (en) Gene silencing
AU2001291656A1 (en) Gene silencing vector
EP1287154A4 (en) NUCLEOTIDES WITH CHARGE SWITCHING
IL158511A0 (en) Selective gene amplification
GB0016702D0 (en) Expression system
GB0019745D0 (en) Gene expression element
GB0007651D0 (en) Gene sequence
GB0026890D0 (en) Catalyst
AU6424701A (en) Gasc1 gene
GB0020320D0 (en) Methods and means for gene silencing
GB0013289D0 (en) Location system
GB2362383B (en) Gene expression system
GB0021667D0 (en) Genetic study
GB0005856D0 (en) Genetic constructs
GB0102936D0 (en) Gene Silencing Gene
PL341185A1 (en) Silencer
GB0006876D0 (en) Gene silencing gene
ZA200207428B (en) Genetic silencing.
LU90708B1 (en) Lihtweight construction
GB0117601D0 (en) Pipe-chamfering means
GB0013511D0 (en) Catalyst
GB2359781B (en) Publication
GB0029864D0 (en) Functional genetic variants
AUPR270001A0 (en) Genetic silencing

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)